Safety and longterm efficacy of maintenance therapy with alternating azacytidine (AZA) and lenalidomide (Len) cycles in elderly (≥ 60) fit patients (Pts) with poor prognosis AML in first complete remission (CR) after LIA induction. A phase II multicentric GOELAMS trial - Hunault, M; Maillard, N; Tanguy-Schmidt, A (Blood, 2015)